摘要
目的探讨新辅助化疗对Ⅲ期乳腺癌的临床疗效及5年生存率的影响。方法将临床分期为Ⅲ期的乳腺癌随机分组为两组,A 组为 CAF+CF 方案化疗2个周期后,2周手术;B 组为术前未行化疗组。手术用标准根治术,术后常规综合治疗。结果 A 组5年生存率为70%,明显高于 B 组30%,差异有统计学意义(P<0.05)。化疗有效组5年生存率高于无效组。结论Ⅲ期乳腺癌有效的术前化疗可提高5年生存率。
Objective To investigate the influence ot new assist cnemomerapy ased in stage Ⅲ breast cancer patients and the clinical effect and improvement of 5 years survival rate. Methods Clinical stage Ⅲ breast cancer patients were randomly divided into two groups. Group A used CAF ＋ CF and then were received operation after two weeks. Group B patients were received no chemotherapy before operation,only standard radical operation and routine combine therapy were applied. Results The 5 years survival rate in group A was 70% , remarkablly higher than 30 % in group B, and the difference is statistically meaningful（ P 〈 0.05）. The 5 years survival rate in chemotherapy effective group was higher than that of chemotherapy effectiveiess group. Conclusion Preoperative effective chemotherapy in stage Ⅲ breast cancer patients can improve 5 years survival rate.
出处
《中国基层医药》
CAS
2007年第7期1169-1170,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
乳腺癌
生存率
新辅助化疗
Breast cancer
Survival rate
New assist chemotherapy
